Found 35 Enz. Inhib. hit(s) with all data for entry = 9841 
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 550nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 550nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+3nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+3nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+3nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+3nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+3nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+3nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+3nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+3nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+3nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+3nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+3nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+3nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+3nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+3nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 5.50E+3nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:The ability of the compounds disclosed herein to inhibit human plasma kallikrein activity was quantified according to the procedures below.A 10 mM so...More data for this Ligand-Target Pair
Affinity DataEC50: <100nMAssay Description:All dilutions were prepared in an assay buffer comprising 50 mM Tris-HCl pH 7.2, 150 mM NaCl, and 0.01% Triton X-100.Four fold serial dilutions were ...More data for this Ligand-Target Pair
Affinity DataEC50: <100nMAssay Description:All dilutions were prepared in an assay buffer comprising 50 mM Tris-HCl pH 7.2, 150 mM NaCl, and 0.01% Triton X-100.Four fold serial dilutions were ...More data for this Ligand-Target Pair
Affinity DataEC50: <100nMAssay Description:All dilutions were prepared in an assay buffer comprising 50 mM Tris-HCl pH 7.2, 150 mM NaCl, and 0.01% Triton X-100.Four fold serial dilutions were ...More data for this Ligand-Target Pair
Affinity DataEC50: <100nMAssay Description:All dilutions were prepared in an assay buffer comprising 50 mM Tris-HCl pH 7.2, 150 mM NaCl, and 0.01% Triton X-100.Four fold serial dilutions were ...More data for this Ligand-Target Pair
Affinity DataEC50: <100nMAssay Description:All dilutions were prepared in an assay buffer comprising 50 mM Tris-HCl pH 7.2, 150 mM NaCl, and 0.01% Triton X-100.Four fold serial dilutions were ...More data for this Ligand-Target Pair
